Northern Trust’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-847,737
| Closed | -$3.56M | – | 4676 |
|
|
2023
Q1 | $3.56M | Sell |
847,737
-15,669
| -2% | -$81.3K | ﹤0.01% | 2657 |
|
|
2022
Q4 | $5.19M | Buy |
863,406
+58,887
| +7% | +$321K | ﹤0.01% | 2461 |
|
|
2022
Q3 | $4.68M | Buy |
804,519
+49,100
| +6% | +$306K | ﹤0.01% | 2532 |
|
|
2022
Q2 | $4.51M | Buy |
755,419
+621,234
| +463% | +$3.18M | ﹤0.01% | 2585 |
|
|
2022
Q1 | $627K | Sell |
134,185
-1,508
| -1% | -$4.5K | ﹤0.01% | 3646 |
|
|
2021
Q4 | $337K | Buy |
135,693
+9,434
| +7% | +$23.1K | ﹤0.01% | 3968 |
|
|
2021
Q3 | $373K | Hold |
126,259
| – | – | ﹤0.01% | 3877 |
|
|
2021
Q2 | $316K | Buy |
126,259
+25,506
| +25% | +$61.2K | ﹤0.01% | 3913 |
|
|
2021
Q1 | $294K | Buy |
100,753
+2,638
| +3% | +$8.61K | ﹤0.01% | 3988 |
|
|
2020
Q4 | $316K | Sell |
98,115
-6,287
| -6% | -$20.9K | ﹤0.01% | 3847 |
|
|
2020
Q3 | $224K | Buy |
104,402
+7,031
| +7% | +$8.98K | ﹤0.01% | 3794 |
|
|
2020
Q2 | $113K | Sell |
97,371
-15,902
| -14% | -$16.8K | ﹤0.01% | 3888 |
|
|
2020
Q1 | $104K | Buy |
113,273
+24,211
| +27% | +$27.7K | ﹤0.01% | 3810 |
|
|
2019
Q4 | $141K | Sell |
89,062
-15,803
| -15% | -$15K | ﹤0.01% | 3871 |
|
|
2019
Q3 | $88K | Sell |
104,865
-433,425
| -81% | -$331K | ﹤0.01% | 3945 |
|
|
2019
Q2 | $463K | Sell |
538,290
-29,433
| -5% | -$27.2K | ﹤0.01% | 3574 |
|
|
2019
Q1 | $551K | Sell |
567,723
-2,783
| -0.5% | -$2.93K | ﹤0.01% | 3522 |
|
|
2018
Q4 | $418K | Sell |
570,506
-281
| -0% | -$462 | ﹤0.01% | 3594 |
|
|
2018
Q3 | $1.23M | Sell |
570,787
-11,735
| -2% | -$29.1K | ﹤0.01% | 3418 |
|
|
2018
Q2 | $2.9M | Buy |
582,522
+473,498
| +434% | +$2.07M | ﹤0.01% | 2999 |
|
|
2018
Q1 | $425K | Buy |
109,024
+70,299
| +182% | +$247K | ﹤0.01% | 3616 |
|
|
2017
Q4 | $104K | Hold |
38,725
| – | – | ﹤0.01% | 3963 |
|
|
2017
Q3 | $123K | Hold |
38,725
| – | – | ﹤0.01% | 3903 |
|
|
2017
Q2 | $128K | Hold |
38,725
| – | – | ﹤0.01% | 3916 |
|
|
2017
Q1 | $163K | Buy |
38,725
+1,407
| +4% | +$6.49K | ﹤0.01% | 3846 |
|
|
2016
Q4 | $153K | Buy |
37,318
+260
| +0.7% | +$1.08K | ﹤0.01% | 3819 |
|
|
2016
Q3 | $139K | Sell |
37,058
-33
| -0.1% | -$120 | ﹤0.01% | 3819 |
|
|
2016
Q2 | $126K | Sell |
37,091
-201,085
| -84% | -$923K | ﹤0.01% | 3830 |
|
|
2016
Q1 | $1.26M | Buy |
238,176
+12,294
| +5% | +$98.2K | ﹤0.01% | 3179 |
|
|
2015
Q4 | $2.78M | Buy |
225,882
+52,121
| +30% | +$696K | ﹤0.01% | 2854 |
|
|
2015
Q3 | $2.54M | Buy |
173,761
+14,549
| +9% | +$251K | ﹤0.01% | 2899 |
|
|
2015
Q2 | $3.1M | Sell |
159,212
-3,501
| -2% | -$67.6K | ﹤0.01% | 2815 |
|
|
2015
Q1 | $2.94M | Buy |
162,713
+2,195
| +1% | +$49.4K | ﹤0.01% | 2862 |
|
|
2014
Q4 | $3.79M | Buy |
160,518
+8,244
| +5% | +$191K | ﹤0.01% | 2675 |
|
|
2014
Q3 | $3.69M | Buy |
152,274
+3,662
| +2% | +$95.2K | ﹤0.01% | 2714 |
|
|
2014
Q2 | $4.18M | Sell |
148,612
-19,346
| -12% | -$581K | ﹤0.01% | 2641 |
|
|
2014
Q1 | $5.71M | Sell |
167,958
-9,832
| -6% | -$336K | ﹤0.01% | 2471 |
|
|
2013
Q4 | $3.4M | Buy |
177,790
+33,124
| +23% | +$603K | ﹤0.01% | 2819 |
|
|
2013
Q3 | $2.34M | Buy |
144,666
+99,113
| +218% | +$1.15M | ﹤0.01% | 3007 |
|
|
2013
Q2 | $478K | Buy |
+45,553
| New | +$534K | ﹤0.01% | 3470 |
|
Other funds holding CTIC
Northern Trust's CTIC Position: Q2 2023 in Review
Northern Trust sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 847,737 shares — an estimated $3.56M sold.
Northern Trust first reported a position in CTIC in Q2 2013 and held it in 40 quarters. The position peaked at $5.71M in Q1 2014. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.
- Northern Trust reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
- Northern Trust sold 847,737 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $3.56M.
- Northern Trust first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q2 2013 and held it in 40 quarters.
- Northern Trust's CTI BioPharma Corp. (DE) Common Stock position peaked at $5.71M in Q1 2014.
- 2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.
Based on Northern Trust's 13F filing for Q2 2023, filed 11 Aug 2023.